http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 07:11:10 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2457+at+Guggenheim/26984463.html (Updated - August 27, 2026 7:11 AM EDT) <p>Guggenheim analyst Seamus Fernandez raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $57.00 (from $55.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are updating our model for AMLX's financing and compelling LUCIDITY results — our PT is now $57 (from $55 prior) due to increased avexitide PoS (95% from 90% prior), partially offset by modest equity dilution. Based on our estimated year-end 2027 cash balance and fully diluted share count, our $57 PT now represents a fully diluted market cap of $8.2B. We highlight ASND and RYTM below as http://www.streetinsider.com/Analyst+PT+Change/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2457+at+Guggenheim/26984463.html Thu, 27 Aug 2026 07:11:10 -0400 AMLX http://www.streetinsider.com/Analyst+Comments/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2457+at+Guggenheim/26984463.html (Updated - August 27, 2026 7:11 AM EDT) <p>Guggenheim analyst Seamus Fernandez raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $57.00 (from $55.00) while maintaining a Buy rating.</p><p>The analyst commented: "We are updating our model for AMLX's financing and compelling LUCIDITY results — our PT is now $57 (from $55 prior) due to increased avexitide PoS (95% from 90% prior), partially offset by modest equity dilution. Based on our estimated year-end 2027 cash balance and fully diluted share count, our $57 PT now represents a fully diluted market cap of $8.2B. We highlight ASND and RYTM below as http://www.streetinsider.com/Analyst+Comments/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2457+at+Guggenheim/26984463.html Thu, 27 Aug 2026 07:11:10 -0400 AMLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Bedrosian+Camille+L/26957571.html si-local-file:///var/storage/secattach/20260820/26957571.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Bedrosian+Camille+L/26957571.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Bedrosian+Camille+L/26957571.html si-local-file:///var/storage/secattach/20260820/26957571.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Bedrosian+Camille+L/26957571.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Cohen+Joshua+B/26957572.html si-local-file:///var/storage/secattach/20260820/26957572.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Cohen+Joshua+B/26957572.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Cohen+Joshua+B/26957572.html si-local-file:///var/storage/secattach/20260820/26957572.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Cohen+Joshua+B/26957572.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+FRATES+JAMES+M/26957576.html si-local-file:///var/storage/secattach/20260820/26957576.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+FRATES+JAMES+M/26957576.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+FRATES+JAMES+M/26957576.html si-local-file:///var/storage/secattach/20260820/26957576.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+FRATES+JAMES+M/26957576.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Mazzariello+Gina/26957577.html si-local-file:///var/storage/secattach/20260820/26957577.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Mazzariello+Gina/26957577.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Mazzariello+Gina/26957577.html si-local-file:///var/storage/secattach/20260820/26957577.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Mazzariello+Gina/26957577.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Klee+Justin+B./26957579.html si-local-file:///var/storage/secattach/20260820/26957579.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Klee+Justin+B./26957579.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Klee+Justin+B./26957579.html si-local-file:///var/storage/secattach/20260820/26957579.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+18++Filed+by%3A+Klee+Justin+B./26957579.html Thu, 20 Aug 2026 21:00:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26957258.html si-local-file:///var/storage/secattach/20260820/26957258.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26957258.html Thu, 20 Aug 2026 17:28:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26957258.html si-local-file:///var/storage/secattach/20260820/26957258.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26957258.html Thu, 20 Aug 2026 17:28:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+19/26957260.html si-local-file:///var/storage/secattach/20260820/26957260.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+19/26957260.html Thu, 20 Aug 2026 17:28:00 -0400 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+19/26957260.html si-local-file:///var/storage/secattach/20260820/26957260.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Aug+19/26957260.html Thu, 20 Aug 2026 17:28:00 -0400 AMLX O.30945667 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html <p>Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of 14,090,000 shares of common stock at $35.50 per share, according to a company statement.</p> <p>The Cambridge, Mass.-based company expects gross proceeds of $500.2 million before underwriting discounts, commissions, and other offering expenses. Amylyx has also granted underwriters a 30-day option to purchase up to an additional 2,113,500 shares at the same offering price.</p> <p>The company said it plans to use net proceeds for pre-commercial activities related to its drug candidate avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes.</p> <p>The offering is expected to close on or about http://www.streetinsider.com/Equity+Offerings/Amylyx+prices+%24500M+stock+offering+at+%2435.50+per+share/26951750.html Wed, 19 Aug 2026 23:06:12 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612 http://www.streetinsider.com/Press+Releases/Amylyx+Pharmaceuticals+Announces+Pricing+of+an+Upsized+%24500+Million+Underwritten+Public+Offering+of+Common+Stock/26951749.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being offered by Amylyx. The gross proceeds to Amylyx from this offering are expected to be $500.2 http://www.streetinsider.com/Press+Releases/Amylyx+Pharmaceuticals+Announces+Pricing+of+an+Upsized+%24500+Million+Underwritten+Public+Offering+of+Common+Stock/26951749.html Wed, 19 Aug 2026 23:06:00 -0400 A.03080680 A.14185667 A.36817542 AMLX O.22066148 O.25213119 O.30945667 O.51342612